Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in Mycobacterium tuberculosis

mBio

Volumn 10, Issue 2, 2019, Pages

  Negatu, Dereje Abate ^a,b   Yamada, Yoshiyuki ^a   Xi, Yu ^c   Go, Mei Lin ^c   Zimmerman, Matthew ^d   Ganapathy, Uday ^d   Dartois, Véronique ^d   Gengenbacher, Martin ^d   Dick, Thomas ^d,e  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b St Peter TB Specialized Hospital   (Ethiopia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Allosteric inhibitor; Antibiotic; NTM; Trpe; Tryptophan mimic

Indexed keywords

INDOLEPROPIONIC ACID; TRYPTOPHAN; ANTHRANILATE SYNTHASE; INDOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

AMINO ACID SYNTHESIS; ARTICLE; BINDING SITE; BIOCHEMICAL ANALYSIS; CATALYSIS; CONTROLLED STUDY; GENETIC ANALYSIS; GROWTH INHIBITION; INTESTINE FLORA; MISSENSE MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

ANTHRANILATE SYNTHASE; ANTITUBERCULAR AGENTS; BIOSYNTHETIC PATHWAYS; INDOLES; MYCOBACTERIUM TUBERCULOSIS; TRYPTOPHAN;

EID: 85063962184     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02781-18     Document Type: Article

References (50)

1. Donia MS, Cimermancic P, Schulze CJ, Wieland Brown LC, Martin J, Mitreva M, Clardy J, Linington RG, Fischbach MA. 2014. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158: 1402-1414. https://doi.org/10.1016/j.cell.2014.08.032.
2. Donia MS, Fischbach MA. 2015. Small molecules from the human microbiota. Science 349: 1254766. https://doi.org/10.1126/science.1254766.
3. Mousa WK, Athar B, Merwin NJ, Magarvey NA. 2017. Antibiotics and specialized metabolites from the human microbiota. Nat Prod Rep 34: 1302-1331. https://doi.org/10.1039/C7NP00021A.
4. Roager HM, Licht TR. 2018. Microbial tryptophan catabolites in health and disease. Nat Commun 9: 3294. https://doi.org/10.1038/s41467-018-05470-4.
5. Namasivayam S, Sher A, Glickman MS, Wipperman MF. 2018. The microbiome and tuberculosis: early evidence for cross talk. mBio 9: e01420-18. https://doi.org/10.1128/mBio.01420-18.
6. Dumas A, Corral D, Colom A, Levillain F, Peixoto A, Hudrisier D, Poquet Y, Neyrolles O. 2018. The host microbiota contributes to early protection against lung colonization by Mycobacterium tuberculosis. Front Immunol 9: 2656. https://doi.org/10.3389/fimmu.2018.02656.
7. Young SN, Anderson GM, Gauthier S, Purdy WC. 1980. The origin of indoleacetic acid and indolepropionic acid in rat and human cerebrospinal fluid. J Neurochem 34: 1087-1092. https://doi.org/10.1111/j.1471-4159.1980.tb09944.x.
8. Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, Le A, Cowan TM, Nolan GP, Fischbach MA, Sonnenburg JL. 2017. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551: 648-652. https://doi.org/10.1038/nature24661.
9. Negatu DA, Liu JJJ, Zimmerman M, Kaya F, Dartois V, Aldrich CC, Gengenbacher M, Dick T. 2018. Whole-cell screen of fragment library identifies gut microbiota metabolite indole propionic acid as antitubercular. Antimicrob Agents Chemother 62: e01571-17. https://doi.org/10.1128/AAC.01571-17.
10. Kaufmann SHE. 2018. Indole propionic acid: a small molecule links between gut microbiota and tuberculosis. Antimicrob Agents Chemother 62: e00389-18. https://doi.org/10.1128/AAC.00389-18.
11. Wood MR, Yu EA, Mehta S. 2017. The human microbiome in the fight against tuberculosis. Am J Trop Med Hyg 96: 1274-1284. https://doi.org/10.4269/ajtmh.16-0581.
12. Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, Trauner A, Wallis D, Galaviz S, Huttenhower C, Sacchettini JC, Behar SM, Rubin EJ. 2013. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155: 1296-1308. https://doi.org/10.1016/j.cell.2013.10.045.
13. Wellington S, Nag PP, Michalska K, Johnston SE, Jedrzejczak RP, Kaushik VK, Clatworthy AE, Siddiqi N, McCarren P, Bajrami B, Maltseva NI, Combs S, Fisher SL, Joachimiak A, Schreiber SL, Hung DT. 2017. A smallmolecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat Chem Biol 13: 943-950. https://doi.org/10.1038/nchembio .2420.
14. Morollo AA, Eck MJ. 2001. Structure of the cooperative allosteric anthranilate synthase from Salmonella typhimurium. Nat Struct Biol 8: 243-247. https://doi.org/10.1038/84988.
15. Bashiri G, Johnston JM, Evans GL, Bulloch EM, Goldstone DC, Jirgis EN, Kleinboelting S, Castell A, Ramsay RJ, Manos-Turvey A, Payne RJ, Lott JS, Baker EN. 2015. Structure and inhibition of subunit I of the anthranilate synthase complex of Mycobacterium tuberculosis and expression of the active complex. Acta Crystallogr D Biol Crystallogr 71: 2297-2308. https://doi.org/10.1107/S1399004715017216.
16. Lin X, Xu S, Yang Y, Wu J, Wang H, Shen H, Wang H. 2009. Purification and characterization of anthranilate synthase component I (TrpE) from Mycobacterium tuberculosis H37Rv. Protein Expr Purif 64: 8-15. https://doi.org/10.1016/j.pep.2008.09.020.
17. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. 2009. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791. https://doi.org/10.1002/jcc.21256.
18. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461. https://doi.org/10.1002/jcc.21334.
19. Spraggon G, Kim C, Nguyen-Huu X, Yee MC, Yanofsky C, Mills SE. 2001. The structures of anthranilate synthase of Serratia marcescens crystallized in the presence of (i) its substrates, chorismate and glutamine, and a product, glutamate, and (ii) its end-product inhibitor, L-tryptophan. Proc Natl Acad Sci U S A 98: 6021-6026. https://doi.org/10.1073/pnas .111150298.
20. Islam MN, Hitchings R, Kumar S, Fontes FL, Lott JS, Kruh-Garcia NA, Crick DC. 2018. Mechanism of fluorinated anthranilate-induced growth inhibition in Mycobacterium tuberculosis. ACS Infect. https://doi.org/10.1021/acsinfecdis.8b00092.
21. Sasse F, Buchholz M, Berlin J. 1983. Site of action of growth inhibitory tryptophan analogues in Catharanthus roseus cell suspension cultures. Z Naturforsch 38: 910. https://doi.org/10.1515/znc-1983-11-1205.
22. Widholm JM. 1972. Tryptophan biosynthesis in Nicotiana tabacum and Daucus carota cell cultures: site of action of inhibitory tryptophan analogs. Biochim Biophys Acta 261: 44-51. https://doi.org/10.1016/0304-4165(72)90311-X.
23. Matsui K, Miwa K, Sano K. 1987. Two single-base-pair substitutions causing desensitization to tryptophan feedback inhibition of anthranilate synthase and enhanced expression of tryptophan genes of Brevibacterium lactofermentum. J Bacteriol 169: 5330-5332. https://doi .org/10.1128/jb.169.11.5330-5332.1987.
24. Sundaram KS, Venkitasubramanian TA. 1978. Tryptophan uptake by Mycobacterium tuberculosis H37Rv: effect of rifampin and ethambutol. Antimicrob Agents Chemother 13: 726-730. https://doi.org/10.1128/AAC .13.5.726.
25. Abrahams KA, Cox JAG, Futterer K, Rullas J, Ortega-Muro F, Loman NJ, Moynihan PJ, Perez-Herran E, Jimenez E, Esquivias J, Barros D, Ballell L, Alemparte C, Besra GS. 2017. Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface. Sci Rep 7: 9430. https://doi.org/10.1038/s41598-017-09642-y.
26. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF. 1991. New use of BCG for recombinant vaccines. Nature 351: 456-460. https://doi.org/10.1038/351456a0.
27. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84. https://doi.org/10.1046/j.1365-2958.2003.03425.x.
28. Gao YR, Feng N, Chen T, Li de F, Bi LJ. 2015. Structure of the MarR family protein Rv0880 from Mycobacterium tuberculosis. Acta Crystallogr F Struct Biol Commun 71: 741-745. https://doi.org/10.1107/S2053230X15007281.
29. Turkarslan S, Peterson EJ, Rustad TR, Minch KJ, Reiss DJ, Morrison R, Ma S, Price ND, Sherman DR, Baliga NS. 2015. A comprehensive map of genome-wide gene regulation in Mycobacterium tuberculosis. Sci Data 2: 150010. https://doi.org/10.1038/sdata.2015.10.
30. Peterson EJR, Ma S, Sherman DR, Baliga NS. 2016. Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis. Nat Microbiol 1: 16078. https://doi.org/10.1038/nmicrobiol.2016.78.
31. Khanapur M, Alvala M, Prabhakar M, Shiva Kumar K, Edwin RK, Sri Saranya PS, Patel RK, Bulusu G, Misra P, Pal M. 2017. Mycobacterium tuberculosis chorismate mutase: a potential target for TB. Bioorg Med Chem 25: 1725-1736. https://doi.org/10.1016/j.bmc.2017.02.001.
32. Sasso S, Okvist M, Roderer K, Gamper M, Codoni G, Krengel U, Kast P. 2009. Structure and function of a complex between chorismate mutase and DAHP synthase: efficiency boost for the junior partner. EMBO J 28: 2128-2142. https://doi.org/10.1038/emboj.2009.165.
33. Munack S, Roderer K, Okvist M, Kamarauskaite J, Sasso S, van Eerde A, Kast P, Krengel U. 2016. Remote control by inter-enzyme allostery: a novel paradigm for regulation of the shikimate pathway. J Mol Biol 428: 1237-1255. https://doi.org/10.1016/j.jmb.2016.01.001.
34. Wu ML, Aziz DB, Dartois V, Dick T. 2018. NTM drug discovery: status, gaps and the way forward. Drug Discov Today 23: 1502-1519. https://doi.org/10.1016/j.drudis.2018.04.001.
35. Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y. 2018. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol 8: 13. https://doi.org/10.3389/fcimb .2018.00013.
36. Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, Qiu Z, Maher L, Redinbo MR, Phillips RS, Fleet JC, Kortagere S, Mukherjee P, Fasano A, Le Ven J, Nicholson JK, Dumas ME, Khanna KM, Mani S. 2014. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 41: 296-310. https://doi.org/10.1016/j.immuni.2014.06.014.
37. Ranhotra HS, Flannigan KL, Brave M, Mukherjee S, Lukin DJ, Hirota SA, Mani S. 2016. Xenobiotic receptor-mediated regulation of intestinal barrier function and innate immunity. Nucl Recept Res 3: 101199. https://doi.org/10.11131/2016/101199.
38. Hwang IK, Yoo KY, Li H, Park OK, Lee CH, Choi JH, Jeong YG, Lee YL, Kim YM, Kwon YG, Won MH. 2009. Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 87: 2126-2137. https://doi.org/10.1002/jnr.22030.
39. Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao CC, Patel B, Yan R, Blain M, Alvarez JI, Kebir H, Anandasabapathy N, Izquierdo G, Jung S, Obholzer N, Pochet N, Clish CB, Prinz M, Prat A, Antel J, Quintana FJ. 2016. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22: 586-597. https://doi.org/10.1038/nm.4106.
40. Fung TC, Olson CA, Hsiao EY. 2017. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 20: 145-155. https://doi.org/10.1038/nn.4476.
41. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. 2009. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106: 3698-3703. https://doi.org/10.1073/pnas.0812874106.
42. Munita JM, Arias CA. 2016. Mechanisms of antibiotic resistance. Microbiol Spectr 4. https://doi.org/10.1128/microbiolspec.VMBF-0016-2015.
43. Mandelbaum-Shavit F, Barak V, Saheb-Tamimi K, Grossowicz N. 1991. Susceptibility of Legionella pneumophila grown extracellularly and in human monocytes to indole-3-propionic acid. Antimicrob Agents Chemother 35: 2526-2530. https://doi.org/10.1128/AAC.35.12.2526.
44. Chemical Computing Group ULC. 2018. Molecular Operating Environment (MOE), 2016.0802. Chemical Computing Group ULC, Montreal, Quebec, Canada.
45. Gopal P, Yee M, Sarathy J, Low JL, Sarathy JP, Kaya F, Dartois V, Gengenbacher M, Dick T. 2016. Pyrazinamide resistance is caused by two distinct mechanisms: prevention of coenzyme A depletion and loss of virulence factor synthesis. ACS Infect Dis 2: 616-626. https://doi.org/10.1021/acsinfecdis.6b00070.
46. Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go ML, Dick T. 2017. Amphiphilic indole derivatives as antimycobacterial agents: structureactivity relationships and membrane targeting properties. J Med Chem 60: 2745-2763. https://doi.org/10.1021/acs.jmedchem.6b01530.
47. Kaser M, Ruf MT, Hauser J, Marsollier L, Pluschke G. 2009. Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. Appl Environ Microbiol 75: 414-418. https://doi.org/10.1128/AEM.01358-08.
48. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. 1999. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567. https://doi.org/10.1002/(SICI)1522-2683(19991201)20: 18<3551:: AID-ELPS3551_3.0.CO;2-2.
49. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. 2007. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1: 2856-2860. https://doi.org/10.1038/nprot.2006.468.
50. Evans GL, Gamage SA, Bulloch EM, Baker EN, Denny WA, Lott JS. 2014. Repurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosis. Chembiochem 15: 852-864. https://doi.org/10.1002/cbic.201300628.